Exosome-based drug delivery systems for the treatment of diabetes and its complications: current opinion

Abstract

Diabetes medication is based on controlling blood glucose and delaying the onset of related complications and is not a complete cure for diabetes. Conventional drug therapy fails to stop progressive islet β cell failure in diabetic patients. Recent studies have shown that "exosome-based therapy" holds great promise in treating diabetes and its complications. Exosomes are small vesicles that are stable in the bloodstream and can effectively deliver therapeutic drugs to specific tissues or organs through intercellular communication. Using exosomes as carriers for drug delivery offers several advantages. This review summarizes the benefits of exosomal drug delivery systems, drug loading methods, and their applications in treating diabetes and its complications. However, there are still challenges to overcome in using exosomal drug delivery systems, such as large-scale production, assessing the contents of exosomes, and monitoring the safety and effectiveness of the treatment in vivo. In conclusion, this review proposes the therapeutical potential of exosomes as drug carriers for developing novel drugs to provide new strategies for treating diabetes and its complications.

Keywords

Exosomes / drug carrier / diabetes / diabetic complications

References

[1] Di Meglio LA,Oram RA.Type 1 diabetes.Lancet2018;391:2449-62. PMCID:PMC6661119

[2] Haller MJ,Schatz D.Type 1 diabetes mellitus: etiology, presentation, and management.Pediatr Clin North Am2005;52:1553-78

[3] Chen C,Stertmann J,Speier S.Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis.Mol Metab2017;6:943-57 PMCID:PMC5605733

[4] Cho NH,Karuranga S.IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045.Diabetes Res Clin Pract2018;138:271-81.

[5] Harding JL,Magliano DJ,Gregg EW.Global trends in diabetes complications: a review of current evidence.Diabetologia2019;62:3-16.

[6] Barclay A,Marsh K.Dietary management in diabetes.Aust Fam Physician2010;39:579-83

[7] Cannataro R,Cerullo G.Type 1 diabetes management in a competitive athlete: a five-year case report.Physiol Rep2023;11:e15740 PMCID:PMC10319554

[8] Hu C.Therapeutic medications against diabetes: what we have and what we expect.Adv Drug Deliv Rev2019;139:3-15

[9] Zuo P,Yan J.Effects of insulin therapy and oral hypoglycemic agents on glycemic control for type 2 diabetes mellitus patients in china-a case control study.Exp Clin Endocrinol Diabetes2021;129:374-8

[10] Hood JL.A systematic approach to exosome-based translational nanomedicine.Wiley Interdiscip Rev Nanomed Nanobiotechnol2012;4:458-67.

[11] Haney MJ,Zhao Y.Exosomes as drug delivery vehicles for Parkinson's disease therapy.J Control Release2015;207:18-30 PMCID:PMC4430381

[12] Cho JA,Son HY.Exosomes: a new delivery system for tumor antigens in cancer immunotherapy.Int J Cancer2005;114:613-22

[13] de Jong B,Hoenderop JGJ.Recent advances in extracellular vesicles as drug delivery systems and their potential in precision medicine.Pharmaceutics2020;12:1006 PMCID:PMC7690579

[14] Tkach M.Communication by extracellular vesicles: where we are and where we need to go.Cell2016;164:1226-32

[15] Gurunathan S,Kim JH.A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes.Int J Nanomedicine2021;16:1281-312 PMCID:PMC7898217

[16] Lu M.Bioinspired exosome-like therapeutics and delivery nanoplatforms.Biomaterials2020;242:119925

[17] Li SP,Jiang XY.Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools.Acta Pharmacol Sin2018;39:542-51. PMCID:PMC5888690

[18] Antimisiaris SG,Marazioti A.Exosomes and exosome-inspired vesicles for targeted drug delivery.Pharmaceutics2018;10:218 PMCID:PMC6321407

[19] Cheng L.Therapeutically harnessing extracellular vesicles.Nat Rev Drug Discov2022;21:379-99

[20] Doyle LM.Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis.Cells2019;8:727. PMCID:PMC6678302

[21] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[22] Brown TD,Wu D,Mitragotri S.Effect of nanoparticle composition, size, shape, and stiffness on penetration across the blood-brain barrier.ACS Biomater Sci Eng2020;6:4916-28

[23] Abels ER.Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake.Cell Mol Neurobiol2016;36:301-12 PMCID:PMC5546313

[24] van Niel G,Clayton A,Raposo G.Challenges and directions in studying cell-cell communication by extracellular vesicles.Nat Rev Mol Cell Biol2022;23:369-82

[25] Pan BT.Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor.Cell1983;33:967-78.

[26] Johnstone RM,Hammond JR,Turbide C.Vesicle formation during reticulocyte maturation.J Biol Chem1987;262:9412-20

[27] Harding C,Stahl P.Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes.J Cell Biol1983;97:329-39. PMCID:PMC2112509

[28] Ni J,Li J.Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts.Cell Death Dis2021;12:662 PMCID:PMC8253828

[29] Hou J,Zheng X,Liu Y.A nanofiber-based drug depot with high drug loading for sustained release.Int J Pharm2020;583:119397.

[30] Somanathan S,Wilson JM.Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial.Mol Ther2020;28:784-93. PMCID:PMC7054813

[31] Boyes WK.Neurotoxicology of nanomaterials.Chem Res Toxicol2020;33:1121-44 PMCID:PMC8293923

[32] Zhang M,Wang M.Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges.J Mater Chem B2019;7:2421-33

[33] Wiklander OP,O'Loughlin A.Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting.J Extracell Vesicles2015;4:26316 PMCID:PMC4405624

[34] Rana S,Stadel D.Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection.Int J Biochem Cell Biol2012;44:1574-84

[35] Waldenström A,Hellman U.Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells.PLoS One2012;7:e34653 PMCID:PMC3323564

[36] Frydrychowicz M,Madejczyk M,Dworacki G.Exosomes-structure, biogenesis and biological role in non-small-cell lung cancer.Scand J Immunol2015;81:2-10

[37] van der Pol E,Grootemaat AE.Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing.J Thromb Haemost2014;12:1182-92

[38] Gangadaran P,Ahn BC.An update on in vivo imaging of extracellular vesicles as drug delivery vehicles.Front Pharmacol2018;9:169 PMCID:PMC5835830

[39] Ke W.Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).Adv Drug Deliv Rev2021;176:113835. PMCID:PMC8440450

[40] Zhou X,Wang L.The function and clinical application of extracellular vesicles in innate immune regulation.Cell Mol Immunol2020;17:323-34. PMCID:PMC7109106

[41] Sherif AY,Alanazi FK.Engineering of exosomes: steps towards green production of drug delivery system.Curr Drug Targets2019;20:1537-49.

[42] Alvarez-Erviti L,Yin H,Lakhal S.Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.Nat Biotechnol2011;29:341-5

[43] Liang Y,Lu J.Engineering exosomes for targeted drug delivery.Theranostics2021;11:3183-95 PMCID:PMC7847680

[44] Kim MS,Zhao Y.Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.Nanomedicine2016;12:655-64 PMCID:PMC4809755

[45] Sato YT,Sawada S.Engineering hybrid exosomes by membrane fusion with liposomes.Sci Rep2016;6:21933 PMCID:PMC4766490

[46] Fuhrmann G,Mazo M,Stevens MM.Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins.J Control Release2015;205:35-44

[47] Liu Y,Si HB,Xie HQ.Exosomes derived from human urine-derived stem cells overexpressing miR-140-5p alleviate knee osteoarthritis through downregulation of VEGFA in a rat model.Am J Sports Med2022;50:1088-105.

[48] Zhang M,Liu L.Engineered exosomes from different sources for cancer-targeted therapy.Signal Transduct Target Ther2023;8:124 PMCID:PMC10017761

[49] Xu M,Liu B.Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies.Theranostics2021;11:8926-44 PMCID:PMC8419041

[50] Sung BH,Guerrero J.A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells.Nat Commun2020;11:2092. PMCID:PMC7190671

[51] Mehryab F,Shahhosseini S.Exosomes as a next-generation drug delivery system: An update on drug loading approaches, characterization, and clinical application challenges.Acta Biomater2020;113:42-62.

[52] Heinemann L,Ehrmann D.Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.Lancet2018;391:1367-77

[53] Meng H,Liang Y,Zhang X.Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials.Diabetes Metab Res Rev2018;34:e2983

[54] Xiao E.Alternative therapies for diabetes: a comparison of western and traditional chinese medicine (TCM) approaches.Curr Diabetes Rev2018;14:487-96.

[55] Martino MM,Güç E.Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing.Science2014;343:885-8.

[56] Cai SS,Akinade T,Leong KW.Drug delivery carriers with therapeutic functions.Adv Drug Deliv Rev2021;176:113884 PMCID:PMC8440421

[57] Zeynaloo E,Dikici E.Delivery of therapeutic agents and cells to pancreatic islets: Towards a new era in the treatment of diabetes.Mol Aspects Med2022;83:101063

[58] Rodríguez-Morales B,González-Valdez J.Exosome-mediated insulin delivery for the potential treatment of diabetes mellitus.Pharmaceutics2021;13:1870 PMCID:PMC8621140

[59] Aqil F,Jeyabalan J,Gupta R.Exosomes for the enhanced tissue bioavailability and efficacy of curcumin.AAPS J2017;19:1691-702.

[60] Zhuang M,Pu L.SPION-decorated exosome delivered BAY55-9837 targeting the pancreas through magnetism to improve the blood GLC response.Small2019;15:e1903135

[61] Xu M,Dong Y.Liraglutide-loaded milk exosomes lower blood glucose when given by sublingual route.ChemMedChem2022;17:e202100758.

[62] Cione E,Gallelli L,Caroleo MC.Exosome microRNAs in metabolic syndrome as tools for the early monitoring of diabetes and possible therapeutic options.Pharmaceuticals2021;14:1257 PMCID:PMC8706321

[63] Wilkinson HN.Wound healing: cellular mechanisms and pathological outcomes.Open Biol2020;10:200223 PMCID:PMC7536089

[64] Soliman AM,Abd Ghafar N.Role of microRNA in proliferation phase of wound healing.Front Genet2018;9:38 PMCID:PMC5817091

[65] Yu P,Li J.lncRNA-H19 in fibroblasts promotes wound healing in diabetes.Diabetes2022;71:1562-78

[66] Li X,Li B,Zhou D.Noncoding RNAs and RNA-binding proteins in diabetic wound healing.Bioorg Med Chem Lett2021;50:128311.

[67] Shende P.siRNA: an alternative treatment for diabetes and associated conditions.J Drug Target2019;27:174-82

[68] Pal D. Chapter 8-miRNAs in diabetic wound healing. In: wound healing, tissue repair, and regeneration in diabetes. Academic Press; 2020.p.149-66.

[69] Ha M.Regulation of microRNA biogenesis.Nat Rev Mol Cell Biol2014;15:509-24

[70] Panico A,Leo CG.The influence of lifestyle factors on miRNA expression and signal pathways: a review.Epigenomics2021;13:145-64.

[71] Chen X,Ma L.Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.Cell Res2008;18:997-1006.

[72] Yan C,Wang C.Milk exosomes-mediated miR-31-5p delivery accelerates diabetic wound healing through promoting angiogenesis.Drug Deliv2022;29:214-28 PMCID:PMC8741248

[73] Huang J,Yin W.Development of a novel RNAi therapy: engineered miR-31 exosomes promoted the healing of diabetic wounds.Bioact Mater2021;6:2841-53 PMCID:PMC7905076

[74] Lv Q,Chen Y,Liu B.Engineered human adipose stem-cell-derived exosomes loaded with miR-21-5p to promote diabetic cutaneous wound healing.Mol Pharm2020;17:1723-33

[75] Born LJ,Shoureshi P.HOTAIR-loaded mesenchymal stem/stromal cell extracellular vesicles enhance angiogenesis and wound healing.Adv Healthc Mater2022;11:e2002070 PMCID:PMC8522167

[76] Wang Y,Wei Q.VH298-loaded extracellular vesicles released from gelatin methacryloyl hydrogel facilitate diabetic wound healing by HIF-1α-mediated enhancement of angiogenesis.Acta Biomater2022;147:342-55.

[77] Xiang X,Jiang T.Milk-derived exosomes carrying siRNA-KEAP1 promote diabetic wound healing by improving oxidative stress.Drug Deliv Transl Res2023;13:2286-96 PMCID:PMC9904251

[78] Pop-Busui R,Feldman EL.Diabetic neuropathy: a position statement by the american diabetes association.Diabetes Care2017;40:136-54. PMCID:PMC6977405

[79] Feldman EL,Jensen TS.New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain.Neuron2017;93:1296-313. PMCID:PMC5400015

[80] Khdour MR.Treatment of diabetic peripheral neuropathy: a review.J Pharm Pharmacol2020;72:863-72

[81] Zheng M,Ma X,Gao X.Harnessing exosomes for the development of brain drug delivery systems.Bioconjug Chem2019;30:994-1005.

[82] Yang H,Ye Y.New perspective in diabetic neuropathy: from the periphery to the brain, a call for early detection, and precision medicine.Front Endocrinol2019;10:929 PMCID:PMC6978915

[83] Singh A,Shiekh PA.Transplantation of engineered exosomes derived from bone marrow mesenchymal stromal cells ameliorate diabetic peripheral neuropathy under electrical stimulation.Bioact Mater2021;6:2231-49 PMCID:PMC7829156

[84] Fan B,Zhang ZG.Treatment of diabetic peripheral neuropathy with engineered mesenchymal stromal cell-derived exosomes enriched with microRNA-146a provide amplified therapeutic efficacy.Exp Neurol2021;341:113694. PMCID:PMC8169562

[85] Rodríguez ML,Mena-Mollá S,Ortega ÁL.Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies.Oxid Med Cell Longev2019;2019:4940825 PMCID:PMC6878793

[86] Simó-Servat O,Simó R.Diabetic retinopathy in the context of patients with diabetes.Ophthalmic Res2019;62:211-7

[87] Pan Q,Lan Q.Exosomes derived from mesenchymal stem cells ameliorate hypoxia/reoxygenation-injured ECs via transferring microRNA-126.Stem Cells Int2019;2019:2831756 PMCID:PMC6589209

[88] Ying W,Bandyopadhyay G.Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity.Cell2017;171:372-84.e12

[89] Ferrante SC,Pillai DK.Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease.Pediatr Res2015;77:447-54. PMCID:PMC4346410

[90] Deng ZB,Hardy RW.Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance.Diabetes2009;58:2498-505. PMCID:PMC2768161

[91] Mathieu M,Lavieu G.Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication.Nat Cell Biol2019;21:9-17

[92] Yang D,Zhang H.Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics.Theranostics2020;10:3684-707 PMCID:PMC7069071

[93] Fernandes TG,Diogo MM.Stem cell bioprocessing for regenerative medicine: Stem cell bioprocessing.J Chem Technol Biotechnol2014;89:34-47

[94] Yabu H.Self-organized precipitation: an emerging method for preparation of unique polymer particles.Polym J2013;45:261-8

[95] Colao IL,Bracewell D.Manufacturing exosomes: a promising therapeutic platform.Trends Mol Med2018;24:242-56

[96] Agrahari V.Challenges associated and approaches for successful translation of nanomedicines into commercial products.Nanomedicine2017;12:819-23.

[97] Taylor DD.Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes.Methods2015;87:3-10

[98] Chen YS,Chiou TW.Exosomes in clinical trial and their production in compliance with good manufacturing practice.Tzu Chi Med J2020;32:113-20 PMCID:PMC7137364

[99] Armstrong JPK.Strategic design of extracellular vesicle drug delivery systems.Adv Drug Deliv Rev2018;130:12-6 PMCID:PMC6606438

[100] Patil SM,Kunda NK.Exosomes as drug delivery systems: a brief overview and progress update.Eur J Pharm Biopharm2020;154:259-69.

[101] Boriachek K,Möller A.Biological functions and current advances in isolation and detection strategies for exosome nanovesicles.Small2018;14:1702153.

[102] Li M,Du C.Exosomes from different cells: characteristics, modifications, and therapeutic applications.Eur J Med Chem2020;207:112784.

[103] Liu G,Chen G.The potential therapeutic value and application prospect of engineered exosomes in human diseases.Front Cell Dev Biol2022;10:1051380 PMCID:PMC9751586

[104] Zhou M,Zhao Y,Sundstrom JM.Chapter 2-Methods for exosome isolation and characterization. Exosomes: Academic Press; 2020 .p.23-38.

[105] Perocheau D,Gurung S,Baruteau J.Clinical applications for exosomes: are we there yet?.Br J Pharmacol2021;178:2375-92. PMCID:PMC8432553